

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 286)**

### **(1) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND**

### **(2) RESIGNATION OF NON-EXECUTIVE DIRECTOR**

#### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. Hou Kaiwen has been appointed as a non-executive Director with effect from 5 June 2017.

#### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. Bai Yinghai resigned as non-executive Director with effect from 5 June 2017.

#### **APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

This announcement is made by Common Splendor International Health Industry Group Limited (“**Company**”) in accordance with Rule 13.51(2) of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The board of directors (“**Board**”) of the Company is pleased to announce that Mr. Hou Kaiwen (“**Mr. Hou**”) has been appointed as a non-executive director of the Company (“**Director**”) with effect from 5 June 2017.

Pursuant to the Company’s Bye-Laws, Mr. Hou is subject to retirement and be eligible for re-election at the forthcoming annual general meeting of the Company.

The biographical details of Mr. Hou is set out below:

**Mr. Hou Kaiwen** (侯凱文), aged 32, obtained a Bachelor's degree in Business Administration and Mathematics from Aston University in Birmingham, the United Kingdom in 2010. Subsequently, Mr. Hou obtained a Master's degree in International Accounting & Finance from London Cass Business School, City University in 2011. Mr. Hou joined the Banking Division of Guosen Securities Investment in May 2012, and he was principally responsible for initial public offering and capital markets related matters. He was involved in a number of healthcare and medical care related initial public offerings in the past. In February 2016, Mr. Hou joined Great Wall Pan Asia International Investment Company Limited as a vice president, and since then, he was mainly responsible for investments in healthcare related businesses.

Save as disclosed above, Mr. Hou (i) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company (as respectively defined in the Listing Rules); (ii) does not have and is not deemed to have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) has not held any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) does not hold any other positions in the Company and its subsidiaries as at the date of this announcement.

Mr. Hou will hold office for an initial term of one year commencing on 5 June 2017, which will continue thereafter. During Mr. Hou's tenure, his appointment may be terminated by either party giving the other not less than one month's notice in writing. According to the terms of appointment, no director's fee will be payable to Mr. Hou but Mr. Hou is entitled to the reimbursement of all reasonable out-of-pocket expenses incurred in relation to the discharge of his duties to the Company. Mr. Hou will be entitled to, if any, discretionary bonus to be determined at the discretion of the Board and the remuneration committee of the Board.

As disclosed in the Company's announcement dated 5 August 2016, the Company issued convertible bonds of an aggregate principal amount of US\$10,000,000 to Great Wall Pan Asia International Investment Co., Limited. The Board believes that, with Mr. Hou's knowledge in capital markets and healthcare related investments, it is in the interest of the Company and its shareholders as a whole to appoint Mr. Hou as a non-executive Director of the Company following Mr. Bai's resignation with a view to providing strategic guidance and support to the Board, from both the capital markets and healthcare industry perspectives, for the growth and development of the Group.

## **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The Board announces that Mr. Bai Yinghai (“**Mr. Bai**”) has tendered his resignation as non-executive Director due to his business commitments with effect from 5 June 2017.

Mr. Bai has confirmed that he has no disagreement with the Board and there are no matters in relation to his resignation that need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to extend its welcome to Mr. Hou for joining the Board and express its sincere gratitude to Mr. Bai for his valuable contributions to the Company during his tenure of office.

By order of the Board  
**Common Splendor International  
Health Industry Group Limited**  
**Cheung Wai Kuen**  
*Chairman*

Hong Kong, 5 June 2017

*As at the date of this announcement, the Board comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors and Mr. Lin Jiang and Mr. Hou Kaiwen as non-executive Directors and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Lam Chi Wing as independent non-executive Directors.*